Abstract:To the Editor: Cryopyrin-associated periodic syndrome (CAPS) is a rare congenital autoinflammatory disease caused by mutations in the NLRP3 gene. Previously, CAPS was assumed to include 3 distinct diseases: familial cold-induced autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease (also known as chronic infantile neurologic, cutaneous, and articular syndrome). The general clinical features of CAPS include recurrent fever, skin rashes, joint pain, and systemic inflammation.1 In clinical practice, there is a significant delay between disease onset and diagnosis of CAPS. The median diagnosis delay was 7.3 years (range, 0.3–76 years) according to a report by an international registry on autoinflammatory diseases in the context of the Eurofever project.2 Delayed diagnosis may result in growth retardation, economic and psychological pressure for the patient and family, and antibiotic abuse. Here, we report a case of a 42-month-old girl who had periodic fever for 20 months and was treated as an infectious disease without any improvement; she was ultimately diagnosed as having CAPS. CASE PRESENTATION The patient presented with an urticaria-like rash over her face and trunk on the second day after her birth. The rash worsened in the summer and improved in the winter, but never disappeared (Figs. A and B). She had recurrent fever beginning at 23 months of age, with a maximum body temperature of 39.5°C. The patient was treated with various antibiotics for more than 1 month, but no improvement was noted. Subsequently, she experienced sudden loss of consciousness and a staring-eye gaze lasting for 1 minute, without headache or vomiting. Laboratory tests showed that she had increased peripheral white blood cell counts (17.75 × 109/L; 57% neutrophils and 35.4% lymphocytes), anemia with hemoglobin level of 90 g/L, and increased C-reactive protein levels (44.5 mg/L). She had normal liver and kidney functions. Her immunoglobulin levels and CD4- and CD8-positive cell counts were normal. To rule out the possibility of intracranial infection, lumbar puncture was performed. Examination of cerebrospinal fluid (CSF) revealed an increased open pressure of 160 mm H2O, 97 white blood cells/μL (20% lymphocytes and 80% neutrophils), greater than 3000 mg/L protein, 1.3 mmol/L glucose, 1.08 U/L adenosine deaminase (reference range, 0–19.6 U/L), and 175 U/L lactate dehydrogenase. Cerebrospinal fluid smears and cultures were negative for bacteria, mycobacteria, and fungi. Chest computed tomography (CT) scans showed bilateral pneumonia (Fig. C). Cranial CT scans showed widened sulci and gyri and enlarged lateral ventricles and third ventricle of the cerebrum (Fig. D). Bacterial meningitis was suspected, and empirical antibiotics, including meropenem, cefepime, vancomycin, and linezolid, were administered. The patient's condition remained unchanged; there was no obvious absorption of lung lesions, and she became irritable. Examination of CSF after more than 1 month of treatment revealed 210 white blood cells/μL (32% lymphocytes and 68% neutrophils), greater than 1857 mg/L protein, 0.94 mmol/L glucose, 3 U/L adenosine deaminase, and 157 U/L lactate dehydrogenase; all etiological evidence was obtained. She tested positive on the T-SPOT.TB tests; thus, tuberculosis and tuberculous meningitis were suspected. A diagnostic antituberculosis regimen with isoniazid, rifampin, pyrazinamide, and ethambutol was given. However, gastric fluid was negative for acid-fast smear and Mycobacterium culture. After 6 weeks of treatment, the patient's symptoms persisted and CSF examination results showed no improvement. Additional bone marrow acid-fast smear and Mycobacterium culture were performed and gave negative results. When glucocorticoids (prednisone, 7.5 mg/d, 0.75 mg/kg per day) were added to the regimen, the patient's condition improved dramatically. Moreover, once the glucocorticoids were withdrawn, the symptoms returned. Repeated gastric fluid acid-fast smear and Mycobacterium culture remained negative after 14 months of treatment. After 15 months of antituberculosis treatment, the fever and rash were not improved, and the patient's growth and development were delayed significantly.FIGURE: Urticaria-like rash over the patient's face and trunk (A and B). ChestCT showing bilateral pneumonia (C). CranialCT scans showingwidened sulci and gyri and enlarged lateral ventricles (D). Geneticmutation in NLRP3 of the patient (E) and relative mRNA expression of (F) IL-1β, (G) IL-2, (H) IL-8, (I) IL-10, (J) TNF-α, (K) MKP-1, and (L) NLRP3 of the patient and her parents. F indicates father; M, mother; P, patient.After the patient was admitted to our department, we reviewed all her medical records and the response to glucocorticoid treatment caught our attention. We applied next-generation sequencing using a targeted panel of 535 genes to screen primary immunodeficiency genes in this patient. The heterozygous point mutation G571R (G1711A, chromosome 1:247588456) in exon 3 of the NLRP3 gene was identified; this was a de novo mutation that was not detected in her parents. We further confirmed the mutation by Sanger sequencing (Fig. E). In addition, the plasma level of interleukin (IL)-1β in the patient was increased to 22.3 ± 0.2 pg/mL, whereas IL-1β levels in both her parents were below the lower limit of detection (4 pg/mL) of the enzyme-linked immunosorbent assay kit. Real-time polymerase chain reaction showed that IL-1β mRNA levels were markedly higher in the blood cells from the patient than in those from her father and mother (Fig. F). The relative mRNA levels of other inflammatory cytokines, including IL-2, IL-8, IL-10, and tumor necrosis factor-α, remained normal in the patient compared with those in the healthy parents. Mitogen-activated protein kinase phosphatase-1 (MKP-1), a negative regulator of mitogen-activated protein kinase activity and an indirect marker of the host's inflammation level, was also upregulated in the patient (Figs. G–K). NLRP3 mRNA was not overexpressed in the patient (Fig. L). Based on the combination of clinical symptoms, NLRP3 gene mutation, and increased IL-1β production in the blood, the patient was finally diagnosed as having CAPS. All antituberculosis drugs were discontinued. Although IL-1β inhibition is an effective therapeutic option,3 anakinra, rilonacept, and canakinumab are available in China. Therefore, we treated the patient with prednisolone (15 mg/d, 1.5 mg/kg per day). From the second day, the patient's body temperature returned to normal, her rash subsided, and her condition and appetite improved. Notably, the rash recurred when she had diarrhea or flu during prednisolone treatment, and it usually lasted for 4 to 5 days. The NLRP3 gene encodes the protein cryopyrin; mutations in this gene lead to constitutive activation of caspase 1 and excessive IL-1β secretion and cause inflammatory manifestations. The G1711A mutation is a newly discovered nucleotide mutation in the NLRP3 gene; however, this mutation (previously described as G569R) was first reported in a patient with Muckle-Wells syndrome and later in a patient with neonatal-onset multisystem inflammatory disease.4 The severity of CAPS disease may be related to IL-1β production.4 It is important to precisely diagnose CAPS early and treat the disease immediately to prevent persistent inflammation-induced organ damage. CONCLUSIONS In our case, before the final diagnosis of CAPS, the patient had been misdiagnosed as suffering from infectious diseases and was incorrectly given different antibiotics for approximately 2 years. Physicians are expected to have sufficient knowledge on clinical symptoms of autoinflammatory diseases and list them as differential diagnoses when taken care of a patient who shows “infection-like” symptoms that cannot be explained by infection. Next, they should use available technologies, such as next-generation sequencing, to confirm the genetic diagnosis. Early diagnosis and timely treatment are of great importance to avoid irreversible and severe organ damage and disability due to autoinflammatory diseases. Key Message Cryopyrin-associated periodic syndrome is a rare congenital autoinflammatory disease that shows symptoms similar to those of most infections and can, therefore, be easily misdiagnosed. Genetic detection using next-generation sequencing can facilitate the early diagnosis and treatment of such rare genetic diseases. Tao Li, MD, PhD Shanghai Public Health Clinical CenterFudan UniversityShanghai, ChinaJing Wu, PhDQiaoling Ruan, MDWenhong Zhang, MD, PhD Department of Infectious DiseasesHuashan HospitalFudan UniversityShanghai, ChinaWenhong Zhang, MD, PhD Key Laboratory of MedicalMolecular VirologyShanghai Medical CollegeFudan UniversityShanghai, ChinaPing Liu, MDNing Pei, MDXiuhong Xi, MDShuihua Lu, MD Shanghai Public Health Clinical CenterFudan UniversityShanghai, [email protected]Ning Jiang, PhD Department of Biostatistics andComputational Biology, SKLGSchool of Life SciencesFudan UniversityShanghai, [email protected]

Refining treat-to-target strategies in cryopyrin-associated periodic syndromes: the role of inflammatory markers

Long-term renal outcome of Cryopyrin-associated periodic syndrome (CAPS) under anti-Interleukin-1 therapy

Microarray-based gene expression profiling in patients with cryopyrin-associated periodic syndromes defines a disease-related signature and IL-1-responsive transcripts

The genetic and clinical characteristics and effects of Canakinumab on cryopyrin-associated periodic syndrome: a large pediatric cohort study from China

Clinical characteristics of cryopyrin‐associated periodic syndrome and long‐term real‐world efficacy and tolerability of canakinumab in Japan: results of a nationwide survey

Practical Approach to Diagnosis and Management of IL-1-Mediated Autoinflammatory Diseases (CAPS, TRAPS, MKD, and DIRA)

Pathogenic variants in the NLRP3 LRR domain at position 861 are responsible for a boost-dependent atypical CAPS phenotype.

A Knock-In Mouse Model of Cryopyrin-Associated Periodic Syndromes

SAT0459 Low Dose IL-2 Restores Imbalance Between TH17 and Regulatory T Cells in Patients with Psoriatic Arthritis

Lipopolysaccharide stimulation test on cultured PBMCs assists the discrimination of cryopyrin-associated periodic syndrome from systemic juvenile idiopathic arthritis

Effectiveness and safety of canakinumab in cryopyrin-associated periodic syndrome: a retrospective study in China

Lessons from the Misdiagnosis of Cryopyrin-Associated Periodic Syndrome As an Infection

P02-023 - NLRP3 Mosaicism As a Cause of Late-Onset CAPS

Novel mutation in the NRLP3 manifesting as an intermediate phenotype of cryopyrinopathies

Pathogenic NLRP3 mutants form constitutively active inflammasomes resulting in immune-metabolic limitation of IL-1β production

The discovery of NLRP3 and its function in cryopyrin-associated periodic syndromes and innate immunity

Current status of understanding the pathogenesis and management of patients with NOMID/CINCA

HSP90β controls NLRP3 autoactivation

Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis

Case Report: Efficacy, safety, and favorable long-term outcome of early treatment with IL-1 inhibitors in a patient with chronic infantile neurological cutaneous articular (CINCA) syndrome caused by NLRP3 mosaicism

A rare case of uncharacterized autoinflammatory disease: Patient carrying variations in NLRP3 and TNFRSF1A genes